| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4707
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2020-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111484550-B |
| titleOfInvention |
Dkk-3 protein functional fragment and application thereof |
| abstract |
The disclosure provides a Dkk-3 protein functional fragment and application thereof. In particular, the present disclosure discloses the function of different fragments of the Dkk-3 protein encoded by amino acids in muscle atrophy. Wherein, the N-terminal fragment of the Dkk-3 protein has the complete function of inducing the muscular atrophy, and the L-CDR2-C fragment of the Dkk-3 protein has the function of antagonizing the muscular atrophy induced by the N-terminal fragment. The disclosure also provides a drug for treating muscular atrophy by taking the specific site of the Dkk-3 protein as a target, and the L-CDR2-C fragment of the Dkk-3 protein or the fusion protein thereof can be used as a targeted drug for antagonizing the function of Dkk-3 induced muscular atrophy. |
| priorityDate |
2020-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |